Asia On The Move: China FDA Appoints New Drug Review Head
This article was originally published in PharmAsia News
Sun Xianze has become the China FDA’s fifth deputy commissioner, with a portfolio that includes oversight of drug reviews and approvals. The Chinese payer agency, the Ministry of Human Resources and Social Security, also has two new deputy ministers, while personnel changes have taken place at Takeda and BGI.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.